OSCR trades 22.1% below Wall Street's consensus target of $37.43.
Last 12 months price action with 12-month analyst target path
The base valuation assumes OSCR achieves its forward estimates and maintains a stable P/E multiple of 15.9x. This scenario reflects the blended consensus of 13 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Oscar Health, Inc. (OSCR) has a Wall Street consensus price target of $37.43, based on estimates from 13 covering analysts. With the stock currently trading at $30.65, this represents a potential upside of +22.1%. The company has a market capitalization of $7.95B.
Analyst price targets range from a low of $20.00 to a high of $49.00, representing a 77% spread in expectations. The median target of $36.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 4 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, OSCR trades at a trailing P/E of 12.4x and forward P/E of 15.9x. Analysts expect EPS to grow +17.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $19.17, with bear and bull scenarios of $12.08 and $25.26 respectively. Model confidence stands at 53/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 CLOVClover Health Investments, Corp. | $2.5B | $4.82 | $5.63 | +16.8% | Hold | 88.0x | 9 |
 ALHCAlignment Healthcare, Inc. | $1.5B | $7.34 | $12.29 | +67.4% | Buy | — | 16 |
 ACGLArch Capital Group Ltd. | $37.5B | $107.28 | $112.50 | +4.9% | Hold | 10.6x | 34 |
 BHVNBiohaven Ltd. | $2.2B | $14.48 | $24.67 | +70.4% | Buy | — | 25 |
 MIRAMIRA Pharmaceuticals, Inc. | $24M | $0.57 | — | — | — | — | — |
 UNHUnitedHealth Group Incorporated | $357.9B | $394.15 | $478.68 | +21.4% | Buy | 19.1x | 52 |
 CVSCVS Health Corp. | $107.0B | $83.85 | $109.89 | +31.1% | Buy | 10.4x | 41 |
 CICigna Corporation | $77.7B | $293.59 | $342.08 | +16.5% | Buy | 9.6x | 40 |
 ELVElevance Health Inc. | $92.3B | $425.62 | $466.69 | +9.6% | Buy | 14.7x | 38 |
 CNCCentene Corp. | $34.5B | $69.74 | $75.43 | +8.2% | Buy | 13.2x | 44 |
Quick answers to the most common questions about buying OSCR stock.
The consensus Wall Street price target for OSCR is $37.43, representing 22.1% upside from the current price of $30.65. With 13 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
OSCR has a consensus rating of "Hold" based on 13 Wall Street analysts. The rating breakdown is mixed, with 8 Hold ratings making up the largest segment. The consensus 12-month price target of $37.43 implies 22.1% upside from current levels.
With a forward P/E of 15.8513x, OSCR trades at a relatively low valuation. The consensus target of $37.43 implies 22.1% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $49 for OSCR, while the most conservative target is $20. The consensus of $37.43 represents the median expectation. Our quantitative valuation model projects a bull case target of $25 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
OSCR is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 8 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month OSCR stock forecast based on 13 Wall Street analysts shows a consensus price target of $37.43, with estimates ranging from $20 (bear case) to $49 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $19, with bear/bull scenarios of $12/$25.
Our quantitative valuation model calculates OSCR's fair value at $19 (base case), with a bear case of $12 and bull case of $25. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 53/100.
OSCR trades at a forward P/E ratio of 15.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 12.4x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on OSCR, with a "Hold" consensus rating and $37.43 price target (22.1% upside). 4 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
OSCR analyst price targets range from $20 to $49, a 77% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $37.43 consensus represents the middle ground. Our model's $12-$25 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.